Protein kinase C-beta II (PKC-βII) expression in patients with colorectal cancer

International Journal of Colorectal Disease

Volumn 24, Issue 6, 2009, Pages 641-645

  Spindler, Karen Lise Garm ^a   Lindebjerg, Jan ^a   Lahn, Michael ^b   Kjaer Frifeldt, Sanne ^a   Jakobsen, Anders ^a  

^a LILLEBAELT HOSPITAL   (Denmark)

^b ELI LILLY AND COMPANY   (United States)

Author keywords

Colorectal cancer; Immunohistochemistry; Prognosis; Protein kinase C beta

Indexed keywords

PROTEIN KINASE C BETA; PROTEIN KINASE C BETA 2; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER STAGING; CANCER SURVIVAL; COLORECTAL ADENOCARCINOMA; COLORECTAL CANCER; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; SURVIVAL TIME;

AGED; COLORECTAL NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; NEOPLASM METASTASIS; PROTEIN KINASE C; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 67349100957     PISSN: 01791958     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00384-009-0680-8     Document Type: Article

References (16)

1. Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics, 2002, CA. Cancer J Clin 55:74-108
2. Saunders M, Iveson T (2006) Management of advanced colorectal cancer: state of the art. Br J Cancer 95:131-138
3. Early DS, Fontana L, Davidson NO (2008) Translational approaches to addressing complex genetic pathways in colorectal cancer. Trans Res 151:10-16
4. Gokmen-Polar Y, Murray NR, Velasco MA, Gatalica Z, Fields AP (2001) Elevated protein kinase C betaII is an early promotive event in colon carcinogenesis. Cancer Res 61:1375-1381
5. Yu W, Murray NR, Weems C, Chen L, Guo H, Ethridge R, Ceci JD, Evers BM, Thompson EA, Fields AP (2003) Role of cyclooxygenase 2 in protein kinase C beta II-mediated colon carcinogenesis. J Biol Chem 278:11167-11174
6. Davidson LA, Aymond CM, Jiang YH, Turner ND, Lupton JR, Chapkin RS (1998) Non-invasive detection of fecal protein kinase C betaII and zeta messenger RNA: Putative biomarkers for colon cancer. Carcinogenesis 19:253-257
7. Cesaro P, Raiteri E, Demoz M, Castino R, Baccino FM, Bonelli G, Isidoro C (2001) Expression of protein kinase C beta1 confers resistance to TNFalpha- and paclitaxel-induced apoptosis in HT-29 colon carcinoma cells. Int J Cancer 93:179-184
8. Graff JR, McNulty AM, Hanna KR, Konicek BW, Lynch RL, Bailey SN, Banks C, Capen A, Goode R, Lewis JE, Sams L, Huss KL, Campbell RM, Iversen PW, Neubauer BL, Brown TJ, Musib L, Geeganage S, Thornton D (2005) The protein kinase Cbeta-selective inhibitor, enzastaurin (LY317615.HCl), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts. Cancer Res 65:7462-7469
9. Wang MY, Acosta K, Theiss N et al (2007) Development of an automated immunohistochemistry assay to detect protein kinase C-bII and its application to breast cancer. Presented at The Tucson Symposium, Tucson, AZ, March 6-7, 2007 (abstr 7645)
10. Raponi M, Winkler H, Dracopoli NC (2008) KRAS mutations predict response to EGFR inhibitors. Curr Opin Pharmacol 8(4):413-418
11. Kim J, Choi YL, Vallentin A, Hunrichs BS, Hellerstein MK, Peehl DM, Mochly-Rosen D (2008) Centrosomal PKCbetaII and pericentrin are critical for human prostate cancer growth and angiogenesis. Cancer Res 68:6831-6839
12. Goekjian PG, Jirousek MR (2001) Protein kinase C inhibitors as novel anticancer drugs. Expert Opin Investig Drugs 10:2117-2140
13. Lahn M, McClelland P, Ballard D, Mintze K, Thornton D, Sandusky G (2006) Immunohistochemical detection of protein kinase C-beta (PKC-beta) in tumour specimens of patients with non-small cell lung cancer. Histopathology 49:429-431
14. Oh Y, Herbst RS, Burris H, Cleverly A, Musib L, Lahn M, Bepler G (2008) Enzastaurin, an oral serine/threonine kinase inhibitor, as second- or third-line therapy of non-small-cell lung cancer. J Clin Oncol 26:1135-1141
15. Spicer SS, Spevey MA et al (1994) Some ascites monoclonal antibody preparations contain contaminants that bind to selected Golgi zones or mast cells. J Histochem Cytochem 42(2):213-221
16. Parker PJ, Murray-Rust J (2004) PKC at a glance. J Cell Sci 117:131-132